Caliper Life Sciences, Inc. (NASDAQ:CALP), a leading provider of tools and services for drug discovery and life sciences research, recently announced the availability of its General Side Effects Profile (GENSEP™), a service offering through its Caliper Discovery Alliances and Services (CDAS) unit, to assess the potential for safety liabilities of drugs under Good Laboratory Practices (GLP).